Anti-PCSK9 Monotherapy for Hypercholesterolemia – The MENDEL-2 Randomized, Controlled Phase 3 Clinical Trial of Evolocumab

Study Questions:

What is the relative efficacy of biweekly and monthly subcutaneous (SC) evolocumab, a monoclonal antibody-based PCSK9 inhibitor, with placebo and oral ezetimibe in patients with hypercholesterolemia in a phase 3 trial?